Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Idelalisib

FDA-approved product (tablet, oral), marketed as Idelalisib, Zydelig.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Idelalisib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm
  • Neoplasm of mature B-cells
  • Non-Hodgkins lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phosphatidylinositol-3-kinase (pi3k) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Idelalisib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Idelalisib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCT07218341 · start 2026-03-09

    Registered record
    Registry ID
    NCT07218341
    Conditions
    Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
    Interventions
    Pirtobrutinib; Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-09
    Completion
    2032-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
    InterventionPirtobrutinib; Idelalisib
    PhasePhase 4
    Registry statusRecruiting

  • A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

    NCT06736990 · start 2025-06-20

    Registered record
    Registry ID
    NCT06736990
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    CAL101; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-06-20
    Completion
    2027-02
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionCAL101; Placebo
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    NCT06846671 · start 2025-04-10

    Registered record
    Registry ID
    NCT06846671
    Conditions
    CLL; Chronic Lymphocytic Leukemia
    Interventions
    Tacabrutideg; Bendamustine; Idelalisib; Rituximab; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-10
    Completion
    2030-02-14
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCLL; Chronic Lymphocytic Leukemia
    InterventionTacabrutideg; Bendamustine; Idelalisib; Rituximab +1 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

    NCT06205290 · start 2024-01-16

    Registered record
    Registry ID
    NCT06205290
    Conditions
    Leukemia, Lymphocytic, Chronic, B-Cell
    Interventions
    Liso-cel; Idelalisib; Rituximab; Bendamustine; Fludarabine; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2024-01-16
    Completion
    2031-10-13
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Lymphocytic, Chronic, B-Cell
    InterventionLiso-cel; Idelalisib; Rituximab; Bendamustine +2 more
    PhasePhase 3
    Registry statusWithdrawn

  • Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

    NCT04699461 · start 2021-11-04

    Registered record
    Registry ID
    NCT04699461
    Conditions
    Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma
    Interventions
    Loncastuximab Tesirine; Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-11-04
    Completion
    2022-11-25
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Follicular Lymphoma; Refractory Follicular Lymphoma
    InterventionLoncastuximab Tesirine; Idelalisib
    PhasePhase 2
    Registry statusTerminated

  • Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    NCT04666038 · start 2021-03-09

    Registered record
    Registry ID
    NCT04666038
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib; Idelalisib; Bendamustine; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-03-09
    Completion
    2027-05
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionPirtobrutinib; Idelalisib; Bendamustine; Rituximab
    PhasePhase 3
    Registry statusActive not recruiting

  • A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma

    NCT04379167 · start 2020-12-30

    Registered record
    Registry ID
    NCT04379167
    Conditions
    Follicular Lymphoma
    Interventions
    YY-20394
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-12-30
    Completion
    2022-12-30
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma
    InterventionYY-20394
    PhasePhase 2
    Registry statusUnknown

  • Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

    NCT03639324 · start 2020-10-02

    Registered record
    Registry ID
    NCT03639324
    Conditions
    Chronic Lymphocytic Leukemia; CLL; Relapsed CLL; Refractory Chronic Lymphocytic Leukemia; Relapsed Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; SLL; Relapsed Small Lymphocytic Lymphoma; Refractory Small Lymphocytic Lymphoma
    Interventions
    Dose combination 1-1; dose combination 1-2; Dose combination 1-3; dose combination 1-4; Sub-Trial: Dose combination 2-1; Sub-Trial: Dose combination 2-2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2020-10-02
    Completion
    2021-10-18
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; CLL; Relapsed CLL; Refractory Chronic Lymphocytic Leukemia +5 more
    InterventionDose combination 1-1; dose combination 1-2; Dose combination 1-3; dose combination 1-4 +2 more
    PhasePhase 1
    Registry statusWithdrawn

  • Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

    NCT03890289 · start 2019-10-18

    Registered record
    Registry ID
    NCT03890289
    Conditions
    Follicular Lymphoma
    Interventions
    Idelalisib; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-10-18
    Completion
    2023-05-10
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma
    InterventionIdelalisib; Obinutuzumab
    PhasePhase 2
    Registry statusTerminated

  • Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

    NCT03349346 · start 2019-06

    Registered record
    Registry ID
    NCT03349346
    Conditions
    Diffuse Large B-Cell Lymphoma; Mediastinal B-cell Lymphoma
    Interventions
    Idelalisib; Rituximab; Ifosfamide; Carboplatin; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2019-06
    Completion
    2026-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-Cell Lymphoma; Mediastinal B-cell Lymphoma
    InterventionIdelalisib; Rituximab; Ifosfamide; Carboplatin +1 more
    PhasePhase 1
    Registry statusWithdrawn

  • A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

    NCT03740529 · start 2019-03-15

    Registered record
    Registry ID
    NCT03740529
    Conditions
    Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma; B-cell Lymphoma; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib; Venetoclax; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-03-15
    Completion
    2025-12-23
    Enrolment
    803

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma +2 more
    InterventionPirtobrutinib; Venetoclax; Rituximab
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib

    NCT03701438 · start 2018-10-23

    Registered record
    Registry ID
    NCT03701438
    Conditions
    B-cell Malignancies
    Interventions
    Influenza Vaccine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2018-10-23
    Completion
    2019-10-09
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Malignancies
    InterventionInfluenza Vaccine
    PhaseNot recorded
    Registry statusTerminated

  • Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

    NCT03151057 · start 2018-07-31

    Registered record
    Registry ID
    NCT03151057
    Conditions
    B Cells-Tumors; B Cell Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)
    Interventions
    Idelalisib 100 MG; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-07-31
    Completion
    2022-07-20
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB Cells-Tumors; B Cell Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma +1 more
    InterventionIdelalisib 100 MG; Placebo Oral Tablet
    PhasePhase 1
    Registry statusTerminated

  • Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma

    NCT03568929 · start 2018-05-25

    Registered record
    Registry ID
    NCT03568929
    Conditions
    Follicular Non-Hodgkin's Lymphoma Refractory
    Interventions
    Idelalisib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-05-25
    Completion
    2021-10-29
    Enrolment
    257

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Non-Hodgkin's Lymphoma Refractory
    InterventionIdelalisib
    PhaseNot recorded
    Registry statusCompleted

  • 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

    NCT03133221 · start 2017-10-23

    Registered record
    Registry ID
    NCT03133221
    Conditions
    Non Hodgkin Lymphoma; Follicular Lymphoma; Indolent Lymphoma; B-cell Lymphoma; Transformed Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma
    Interventions
    Zydelig
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-10-23
    Completion
    2024-09-29
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Hodgkin Lymphoma; Follicular Lymphoma; Indolent Lymphoma; B-cell Lymphoma +5 more
    InterventionZydelig
    PhasePhase 2
    Registry statusCompleted